Nuage

Nuage Therapeutics

This company develops drug screening assays and small-molecule therapies targeting intrinsically disordered proteins to treat aggressive cancers for the healthcare and pharmaceutical industries.

Neomorph

The company develops molecular glue degraders to target and eliminate disease-causing proteins for pharmaceutical partners and patients with neurological or immune diseases.

Nimbus

This clinical-stage company develops small molecule medicines for patients with cancer, inflammatory diseases and metabolic disorders through a computational drug discovery engine.

VUS Genetics

This company develops high-throughput functional assays for drug developers to classify gene variants and improve patient stratification in oncology and rare disease clinical trials.

Tipping Point Biosciences

This biotechnology company develops a drug discovery platform and small molecule therapies targeting dysfunctional DNA packaging for patients with cancer and neurodegenerative diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Nuclidium

This clinical-stage company develops copper-based radiopharmaceuticals for the diagnosis and treatment of cancer patients.

Shape Therapeutics

The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.